Infectious Burden and Immortal-Time Bias During AML Induction: A Supportive-Care Cohort Under Posaconazole Prophylaxis


Gözden H. E., Tokat H. B., Uluçay H. T., Bayrak F. T., Kaya R., Kocabıyık A. B., ...Daha Fazla

Journal of Clinical Medicine, cilt.15, sa.20, 2026 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 20
  • Basım Tarihi: 2026
  • Doi Numarası: 10.3390/jcm15207841
  • Dergi Adı: Journal of Clinical Medicine
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Chemical Abstracts Core, EMBASE, Academic Search Ultimate (EBSCO), Health Research Premium Collection (ProQuest)
  • Anahtar Kelimeler: acute myeloid leukaemia, supportive care, infection, febrile neutropenia, early mortality, immortal-time bias, real-world evidence
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Background/Objectives: Infection is a major complication of acute myeloid leukaemia (AML) induction, and analyses relating treatment-emergent infection to survival are prone to immortal-time bias. We characterised baseline and treatment-emergent infection during induction and used bias-aware methods to distinguish a pre-treatment risk signal from a survival-time artefact. Methods: Our study analysed a retrospective single-centre cohort of 91 adults with newly diagnosed AML receiving induction under universal posaconazole prophylaxis (2019–2025) with Cox models, 14- and 30-day landmark analyses and Firth penalised logistic regression. Results: Active infection at diagnosis occurred in 23/91 (25.3%) and treatment-emergent infection in 54/91 (59.3%). A naive Cox model showed an implausibly protective association for treatment-emergent infection (hazard ratio [HR] 0.46, 95% CI 0.21–0.99). In 14- and 30-day landmark analyses (HR 0.59 and 0.60; 95% CIs included 1) the estimate moved toward the null and lost statistical significance; because infection-onset dates were unavailable, landmark analysis only partially corrects this bias, and the independent association between treatment-emergent infection and survival could not be reliably estimated. Active infection at diagnosis showed a fragile, exploratory association with later mortality that was nominally significant in only one of several pre-specified specifications (30-day landmark HR 2.56, 95% CI 1.03–6.37). Conclusions: The apparently protective association of treatment-emergent infection with survival is consistent with immortal-time bias; it is a complication and marker of course, not a survival determinant. Baseline infection is a hypothesis-generating candidate pre-treatment risk marker that requires prospective validation.